Myeloid-Derived Suppressor Cells and Radiotherapy

Carlos Jiménez-Cortegana, Claudia Galassi, Vanessa Klapp, Dmitry I. Gabrilovich, Lorenzo Galluzzi*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

26 Citations (Scopus)


Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of pathologically activated, mostly immature, myeloid cells that exert robust immunosuppressive functions. MDSCs expand during oncogenesis and have been linked to accelerated disease progression and resistance to treatment in both preclinical tumor models and patients with cancer. Thus, MDSCs stand out as promising targets for the development of novel immunotherapeutic regimens with superior efficacy. Here, we summarize accumulating preclinical and clinical evidence indicating that MDSCs also hamper the efficacy of radiotherapy (RT), as we critically discuss the potential of MDSC-targeting strategies as tools to achieve superior immunotherapeutic tumor control by RT in the clinic.

Original languageEnglish
Pages (from-to)545-557
Number of pages13
JournalCancer Immunology Research
Issue number5
Publication statusPublished - May 2022
Externally publishedYes


Dive into the research topics of 'Myeloid-Derived Suppressor Cells and Radiotherapy'. Together they form a unique fingerprint.

Cite this